GSK (GSK) grants 2026 deferred notional share awards to two senior executives

Rhea-AI Filing Summary

GSK plc reported that two senior executives received notional share awards under its Deferred Investment Award programme. On 12 February 2026, President Europe Lynn Baxter and Chief Patient Officer Mondher Mahjoubi were each granted awards over 3,020 notional Ordinary Shares at a reference price of £21.41 per share.

The awards are designed to reward outstanding performance during 2025 and align management with shareholders. They vest on 12 February 2029, provided the recipients remain with the company and are not terminated for cause. No dividends accrue during the vesting period and, on vesting, the awards will be settled in cash rather than actual shares. Executive Directors are not eligible to receive awards under this programme.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

2026 Awards under the Deferred Investment Award Programme

Notional Award

On 12 February 2026, the Company granted awards over notional Ordinary Shares to Persons Discharging Managerial Responsibilities ('PDMRs') under the GlaxoSmithKline Deferred Investment Award programme. 

Under the programme, awards are made over notional Ordinary Shares with vesting over a specified period to provide long-term alignment with shareholders. Vesting is subject to the PDMR not having served the Company notice or having been terminated by the Company for cause. No dividends will accrue on the award during the vesting period. On vesting, the award will be paid in cash. Executive Directors are not eligible to receive awards under the programme.  

The awards have been granted to reward outstanding performance during 2025 for two newly appointed Executive Committee members as part of the Company's performance system for the general employee population. The awards will vest on 12 February 2029.

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Lynn Baxter
b)	Position/status	President, Europe
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.41	3,020
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-12
f)	Place of the transaction	N/A

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mondher Mahjoubi
b)	Position/status	Chief Patient Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	A restricted award of notional Ordinary Shares under the Company's Deferred Investment Award programme.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£21.41	3,020
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-02-12
f)	Place of the transaction	N/A

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 16, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc

FAQ

What did GSK (GSK) announce in this Form 6-K filing?

GSK announced notional share awards for two senior executives under its Deferred Investment Award programme. Each received 3,020 notional Ordinary Shares, linked to performance in 2025 and designed to align their incentives with long-term shareholder interests.

Who received the 2026 Deferred Investment Awards at GSK (GSK)?

President Europe Lynn Baxter and Chief Patient Officer Mondher Mahjoubi received the 2026 notional awards. Both are newly appointed Executive Committee members and were recognized for outstanding performance during 2025 under GSK’s performance and reward framework.

How large are the GSK (GSK) notional awards and what is the reference price?

Each executive received an award over 3,020 notional Ordinary Shares with a reference price of £21.41 per share. These values define the notional size of the award used for future cash settlement at vesting, rather than immediate share delivery.

When do the GSK (GSK) Deferred Investment Awards vest and how are they settled?

The awards vest on 12 February 2029, subject to continued employment and no termination for cause. Upon vesting, they are paid entirely in cash, with no actual shares delivered, and no dividends accruing during the vesting period.

Are GSK (GSK) Executive Directors eligible for these Deferred Investment Awards?

Executive Directors are explicitly not eligible for awards under GSK’s Deferred Investment Award programme. The 2026 grants were made only to two newly appointed Executive Committee members as part of the company’s broader performance and reward system.

What is the purpose of GSK’s (GSK) Deferred Investment Award programme?

The programme grants notional Ordinary Share awards that vest over a set period to support long-term alignment with shareholders. It rewards strong performance while encouraging retention, since vesting depends on continued employment and is linked to long-term incentive structures.